Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 235-237

  Garassino, M C ^a   Marabese, M ^b   Rusconi, P ^b   Rulli, E ^b   Martelli, O ^c   Farina, G ^a   Scanni, A ^d   Broggini, M ^b  

^a Fatebenefratelli and Oftalmico Hospital   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; K RAS PROTEIN; PACLITAXEL; PEMETREXED; SORAFENIB;

AMINO ACID SUBSTITUTION; CLINICAL TRIAL; DRUG RESPONSE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 78650372656     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq680     Document Type: Letter

References (5)

1. Janakiraman M, Vakiani E, Zeng Z et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010; 70: 5901-5911.
2. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
3. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010; 28: 4769-4777.
4. Ferté C, Besse B, Dansin E et al. Durable responses to erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Ann Oncol 2010; 21(6): 1385-1387.
5. Prenen H, Tejpar S, Van Cutsem E. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res 2010; 16: 2921-2926.